Harvard Medical School, Bayer, Novartis, Celgene, CMO of Ipsen
Chief Medical Officer, SVP and Head of Global Medical Affairs at Ipsen
Vice President and Head of Global Medical Affairs Oncology for Baxalta Inc and Shire & roles in medical affairs and clinical development at Bayer Pharmaceuticals, Novartis Pharmaceuticals and Celgene Corporation
Trained in Internal Medicine and Cancer Genetics from NIH, Albert Einstein College of Medicine and Harvard Medical School
Masters of Biotechnology Enerprise and Entrepreneurship from Johns Hopkins University
President & CEO, Founder
Sotirios Stergiopoulos, MD, MBEE, FACP
Research and Biotech focused capital markets with Goldman Sachs, Credit Suisse & UBS
MBA from University of Illinois at Urbana-Champaign
Former VP at UBS, Oppenheimer & Co., Credit Suisse, and Kidder Peabody
Former analyst at Goldman Sachs and Salomon Brothers
30 years of experience in finance
Has worked extensively with biotech companies in financing and investment decisions
Chairman & CIO, Founder
Edward Painter, MBA
Medicinal Chemist. Trinity College Dublin, University of Toronto. Consultant and Venture Advisor
Life Science Innovation Specialist with over 8 years of experience in the USA, Canada and Europe Life Science markets.
Experienced in consulting for tier-1 pharma companies and project management for several innovation organizations in North America.
Venture advisor and business developer for diverse biotechnology companies.
Ph.D. medicinal chemistry in the synthesis and bio-evaluation of protein kinase inhibitors for the treatment of cancer at Trinity College Dublin.
Postdoctoral research in Neuroscience at University of Toronto and part-time professorship at San Francisco State University.
Head of Business Development, R&D Strategy
Elena Diez Cecilia, PhD, MBA
Medicinal and Computational Chemist. Seoul National University, University of Pittsburgh, UPCDC
PhD in Synthetic and Medicinal Chemistry from the Seoul National University
Postdoctoral research in Chemistry from the University of Pittsburgh
Extensive research experience in synthetic organic chemistry and drug discovery covering multiple therapeutic areas
Co-authored 20 SCI papers and 9 patent applications as a co-inventor
Has contributed to drug discovery and development projects ranging from early development stages through to preclinical trials particularly using in silico drug design tools
Chief Scientific Officer
Chaemin Lim, PhD
Machine Learning and Computational Chemist
Master in Computer Science, Cornell Tech
Chemist, Univ. South Florida
Bryd Alzheimers Institute, Center of Disease and Drug Innovation Medicinal Chemist
Development of Novel Therapeutics using Cannabinoid analogs for Alzheimer's and Other Neurodegenerative Diseases.
Head of Technology Innovation
Emmanuel Cruz, M.Eng, B.S.
Stanford, University of Toronto, Trinity College Dublin. Consulting with Pfizer, Eli Lilly & currently at LEK
Ph.D. Design, synthesis & evaluation of alpha 2 adrenoceptor antagonists for the treatment of Depession
Postdoctoral research, Stanford University
Collaboration with Pfizer & Eli Lilly on multiple projects
Life Science Specialist at L.E.K. Consulting
Brendan Kelly, PhD
Harvard University Postdoc Leukemia Research, BD Ironwood and Rafael Pharma
PhD in Human Biology from Ludwig-Maximilians University
MBA from Boston University
Postdoctoral research at Harvard University in leukemia and the target of AO-001
Authored several articles in oncology in leading publications
Biotechnology industry analyst experience at Jeffries LLC
Machine Learning and Computational Chemist. University of Pittsburgh
PhD student from University of Pittsburgh
Drug design and compound development experiences in CNS disorders and cancer
In silico modeling and simulations with applications on drug discovery using fragment-based approach
MS in Pharmaceutical Science from University of Pittsburgh